FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118528310> ?p ?o ?g. }

• W3118528310 endingPage "828" @default.
• W3118528310 startingPage "821" @default.
• W3118528310 abstract "Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We conducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. Methods In this two-stage, phase II study (NCT03040986) patients with advanced pancreas cancer harboring somatic KRASG12R variants who had received at least one standard-of-care systemic therapy regimen received 75 mg selumetinib orally twice a day until disease progression or unacceptable toxicity occurred. The primary outcome of the study was best objective response (BOR). Results From August 2017 to February 2018 a total of 8 patients with confirmed somatic KRASG12R mutations and a median age of 61.5 years were treated with selumetinib. Seven out of eight (87.5%) had received two or more lines of prior systemic chemotherapy. After a median follow-up period of 8.5 months (range 2 to 20), three patients had stable disease for more than 6 months while receiving selumetinib. No patients achieved an objective partial response. Median progression-free survival (PFS) was 3.0 months (95% CI, 0.8-8.2) and median overall survival (OS) 9 months (95% CI, 2.5-20.9). Conclusion This study in heavily pre-treated pancreatic adenocarcinoma patients suggests alternative strategies beyond single agent MEK inhibition are required for this unique, molecular subset of pancreatic cancer patients. The trial was registered on February 2nd, 2017 under identifier NCT03040986 with ClinicalTrials.gov ." @default.
• W3118528310 created "2021-01-18" @default.
• W3118528310 creator A5004974541 @default.
• W3118528310 creator A5012311589 @default.
• W3118528310 creator A5018642666 @default.
• W3118528310 creator A5028439777 @default.
• W3118528310 creator A5028944659 @default.
• W3118528310 creator A5044239219 @default.
• W3118528310 creator A5050642526 @default.
• W3118528310 creator A5062980852 @default.
• W3118528310 creator A5072094247 @default.
• W3118528310 date "2021-01-06" @default.
• W3118528310 modified "2023-10-16" @default.
• W3118528310 title "Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma" @default.
• W3118528310 cites W1967856042 @default.
• W3118528310 cites W1968812902 @default.
• W3118528310 cites W2025749621 @default.
• W3118528310 cites W2047975772 @default.
• W3118528310 cites W2062983115 @default.
• W3118528310 cites W2063271214 @default.
• W3118528310 cites W2067826589 @default.
• W3118528310 cites W2081990599 @default.
• W3118528310 cites W2108517627 @default.
• W3118528310 cites W2129400742 @default.
• W3118528310 cites W2141674733 @default.
• W3118528310 cites W2158134441 @default.
• W3118528310 cites W2285093314 @default.
• W3118528310 cites W2563361316 @default.
• W3118528310 cites W2567025368 @default.
• W3118528310 cites W2613467753 @default.
• W3118528310 cites W2790254562 @default.
• W3118528310 cites W2793005533 @default.
• W3118528310 cites W2799710201 @default.
• W3118528310 cites W2981746321 @default.
• W3118528310 cites W2984359187 @default.
• W3118528310 cites W2990030759 @default.
• W3118528310 cites W2999417355 @default.
• W3118528310 cites W3016278644 @default.
• W3118528310 cites W3019894803 @default.
• W3118528310 cites W3033317451 @default.
• W3118528310 doi "https://doi.org/10.1007/s10637-020-01044-8" @default.
• W3118528310 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8068685" @default.
• W3118528310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33405090" @default.
• W3118528310 hasPublicationYear "2021" @default.
• W3118528310 type Work @default.
• W3118528310 sameAs 3118528310 @default.
• W3118528310 citedByCount "18" @default.
• W3118528310 countsByYear W31185283102021 @default.
• W3118528310 countsByYear W31185283102022 @default.
• W3118528310 countsByYear W31185283102023 @default.
• W3118528310 crossrefType "journal-article" @default.
• W3118528310 hasAuthorship W3118528310A5004974541 @default.
• W3118528310 hasAuthorship W3118528310A5012311589 @default.
• W3118528310 hasAuthorship W3118528310A5018642666 @default.
• W3118528310 hasAuthorship W3118528310A5028439777 @default.
• W3118528310 hasAuthorship W3118528310A5028944659 @default.
• W3118528310 hasAuthorship W3118528310A5044239219 @default.
• W3118528310 hasAuthorship W3118528310A5050642526 @default.
• W3118528310 hasAuthorship W3118528310A5062980852 @default.
• W3118528310 hasAuthorship W3118528310A5072094247 @default.
• W3118528310 hasBestOaLocation W31185283101 @default.
• W3118528310 hasConcept C121608353 @default.
• W3118528310 hasConcept C126322002 @default.
• W3118528310 hasConcept C143998085 @default.
• W3118528310 hasConcept C184235292 @default.
• W3118528310 hasConcept C2776087337 @default.
• W3118528310 hasConcept C2776694085 @default.
• W3118528310 hasConcept C2778822529 @default.
• W3118528310 hasConcept C2780210213 @default.
• W3118528310 hasConcept C2781182431 @default.
• W3118528310 hasConcept C2781187634 @default.
• W3118528310 hasConcept C2781249067 @default.
• W3118528310 hasConcept C526805850 @default.
• W3118528310 hasConcept C57074206 @default.
• W3118528310 hasConcept C71924100 @default.
• W3118528310 hasConcept C86803240 @default.
• W3118528310 hasConcept C95444343 @default.
• W3118528310 hasConceptScore W3118528310C121608353 @default.
• W3118528310 hasConceptScore W3118528310C126322002 @default.
• W3118528310 hasConceptScore W3118528310C143998085 @default.
• W3118528310 hasConceptScore W3118528310C184235292 @default.
• W3118528310 hasConceptScore W3118528310C2776087337 @default.
• W3118528310 hasConceptScore W3118528310C2776694085 @default.
• W3118528310 hasConceptScore W3118528310C2778822529 @default.
• W3118528310 hasConceptScore W3118528310C2780210213 @default.
• W3118528310 hasConceptScore W3118528310C2781182431 @default.
• W3118528310 hasConceptScore W3118528310C2781187634 @default.
• W3118528310 hasConceptScore W3118528310C2781249067 @default.
• W3118528310 hasConceptScore W3118528310C526805850 @default.
• W3118528310 hasConceptScore W3118528310C57074206 @default.
• W3118528310 hasConceptScore W3118528310C71924100 @default.
• W3118528310 hasConceptScore W3118528310C86803240 @default.
• W3118528310 hasConceptScore W3118528310C95444343 @default.
• W3118528310 hasIssue "3" @default.
• W3118528310 hasLocation W31185283101 @default.
• W3118528310 hasLocation W31185283102 @default.
• W3118528310 hasLocation W31185283103 @default.
• W3118528310 hasLocation W31185283104 @default.

• next